161 related articles for article (PubMed ID: 1282032)
1. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).
Gedde-Dahl T; Spurkland A; Eriksen JA; Thorsby E; Gaudernack G
Int Immunol; 1992 Nov; 4(11):1331-7. PubMed ID: 1282032
[TBL] [Abstract][Full Text] [Related]
2. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.
Gedde-Dahl T; Spurkland A; Fossum B; Wittinghofer A; Thorsby E; Gaudernack G
Eur J Immunol; 1994 Feb; 24(2):410-4. PubMed ID: 7507844
[TBL] [Abstract][Full Text] [Related]
3. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).
Fossum B; Gedde-Dahl T; Breivik J; Eriksen JA; Spurkland A; Thorsby E; Gaudernack G
Int J Cancer; 1994 Jan; 56(1):40-5. PubMed ID: 7903287
[TBL] [Abstract][Full Text] [Related]
4. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides.
Gedde-Dahl T; Eriksen JA; Thorsby E; Gaudernack G
Hum Immunol; 1992 Apr; 33(4):266-74. PubMed ID: 1639630
[TBL] [Abstract][Full Text] [Related]
5. Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells.
Fossum B; Gedde-Dahl T; Hansen T; Eriksen JA; Thorsby E; Gaudernack G
Eur J Immunol; 1993 Oct; 23(10):2687-91. PubMed ID: 7691613
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation.
Gjertsen MK; Bjorheim J; Saeterdal I; Myklebust J; Gaudernack G
Int J Cancer; 1997 Sep; 72(5):784-90. PubMed ID: 9311595
[TBL] [Abstract][Full Text] [Related]
7. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
8. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
[TBL] [Abstract][Full Text] [Related]
9. Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein.
Escobar P; Yu Z; Terskikh A; Holmes N; Corradin G; Mach JP; Healy F
Clin Exp Immunol; 1999 May; 116(2):214-9. PubMed ID: 10337009
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T-lymphocyte responses against mutated p21 ras peptides: an analysis of specific T-cell-receptor gene usage.
Juretic A; Jürgens-Göbel J; Schaefer C; Noppen C; Willimann TE; Kocher T; Zuber M; Harder F; Heberer M; Spagnoli GC
Int J Cancer; 1996 Nov; 68(4):471-8. PubMed ID: 8945618
[TBL] [Abstract][Full Text] [Related]
11. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.
Peace DJ; Chen W; Nelson H; Cheever MA
J Immunol; 1991 Mar; 146(6):2059-65. PubMed ID: 2005390
[TBL] [Abstract][Full Text] [Related]
12. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
Abrams SI; Dobrzanski MJ; Wells DT; Stanziale SF; Zaremba S; Masuelli L; Kantor JA; Schlom J; Masuelle L [corrected to Masuelli L]
Eur J Immunol; 1995 Sep; 25(9):2588-97. PubMed ID: 7589131
[TBL] [Abstract][Full Text] [Related]
13. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201.
Van Elsas A; Nijman HW; Van der Minne CE; Mourer JS; Kast WM; Melief CJ; Schrier PI
Int J Cancer; 1995 May; 61(3):389-96. PubMed ID: 7729952
[TBL] [Abstract][Full Text] [Related]
14. Modification of human T-cell responses by altered peptide ligands: a new approach to antigen-specific modification.
Nishimura Y; Chen YZ; Kanai T; Yokomizo H; Matsuoka T; Matsushita S
Intern Med; 1998 Oct; 37(10):804-17. PubMed ID: 9840700
[TBL] [Abstract][Full Text] [Related]
15. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
[TBL] [Abstract][Full Text] [Related]
16. Mutations in residue 61 of H-Ras p21 protein influence MHC class II presentation.
Ngo-Giang-Huong N; Kayibanda M; Deprez B; Levy JP; Guillet JG; Tilkin AF
Int Immunol; 1995 Feb; 7(2):269-75. PubMed ID: 7734422
[TBL] [Abstract][Full Text] [Related]
17. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides.
Yokomizo H; Matsushita S; Fujisao S; Murakami S; Fujita H; Shirouzu M; Yokoyama S; Ogawa M; Nishimura Y
Hum Immunol; 1997 Jan; 52(1):22-32. PubMed ID: 9021406
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras.
Gedde-Dahl T; Nilsen E; Thorsby E; Gaudernack G
Cancer Immunol Immunother; 1994 Feb; 38(2):127-34. PubMed ID: 8306368
[TBL] [Abstract][Full Text] [Related]
20. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
Cheever MA; Chen W; Disis ML; Takahashi M; Peace DJ
Ann N Y Acad Sci; 1993 Aug; 690():101-12. PubMed ID: 8103658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
